Please assess the completion status of the following clinical trial:

Trial Title: A Study of DS-8201a in Metastatic Breast Cancer Previously Treated With Trastuzumab Emtansine (T-DM1)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Men or women the age of majority in their country~* Has pathologically documented breast cancer that:~  1. is unresectable or metastatic~ 2. has HER2 positive expression confirmed per protocol~* Has an adequate tumor sample~* Has at least one measurable lesion per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1~* Has protocol-defined adequate cardiac, renal and hepatic function~* Agrees to follow protocol-defined method(s) of contraception~Exclusion Criteria:~* Has a medical history of myocardial infarction, symptomatic congestive heart failure (CHF) (NYHA classes II-IV), unstable angina or serious cardiac arrhythmia~* Has a corrected QT interval (QTc) prolongation to \> 450 millisecond (ms) in males and \> 470 ms in females~* Has a medical history of clinically significant lung disease~* Is suspected to have certain other protocol-defined diseases based on imaging at screening period~* Has history of any disease, metastatic condition, drug/medication use or other condition that might, per protocol or in the opinion of the investigator, compromise:~  1. safety or well-being of the participant or offspring~ 2. safety of study staff~ 3. analysis of results

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- DS-8201a Low Dose (Type: EXPERIMENTAL): T-DM1 resistant/refractory (R/R) patients in the low dose treatment group
- DS-8201a Medium Dose (Type: EXPERIMENTAL): T-DM1 resistant/refractory (R/R) patients in the medium dose treatment group
- DS-8201a High Dose (Type: EXPERIMENTAL): T-DM1 resistant/refractory (R/R) patients in the high dose treatment group
- Exploratory Arm (Type: OTHER): In Part 2b- Continuation Stage, about 10 T-DM1 Intolerant patients will receive the DS-8201a recommended dose (RD) as an exploratory arm

Based on this trial design, predict the completion outcome and termination type (if applicable).